Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 4:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 10,356 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Congenital, Hereditary, and Neonatal Diseases and Abnormalities Clear all

Conditions: Atopic Dermatitis
Interventions: MEDI3506, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 13
States / cities: Birmingham, Alabama • Santa Monica, California • Jacksonville, Florida + 9 more

Conditions: Pain
Interventions: SMART app wearable; Other
Lead sponsor: Duke University; Other
Eligibility: 8 Years to 80 Years
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hemophilia A With Inhibitor, Hemophilia A
Interventions: Wilate; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Sacramento, California • San Diego, California • New Orleans, Louisiana

Conditions: Prader-Willi Syndrome
Interventions: 3.2 mg intranasal carbetocin, 9.6 mg intranasal carbetocin, placebo; Drug
Lead sponsor: Levo Therapeutics, Inc.; Industry
Eligibility: 7 Years to 18 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more

Conditions: Obesity and Obesity-related Medical Conditions, Diabetes, Atherosclerotic Disease, Heart Failure, MASH, Sarcopenia, Osteoporosis, Hyperparathyroidism, Hypoparathyroidism, Ischemic Heart Disease, Cystic Fibrosis (CF), Chronic Kidney Disease(CKD), Osteopenia, Cachexia
Interventions: Endothelial cell collection; Other
Lead sponsor: Bettina Mittendorfer; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Multiple Endocrine Neoplasia Syndromes
Interventions: Questionnaires; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fanconi Anemia, Head and Neck Cancer, Squamous Cell Carcinoma, Squamous Cell Cancer of Head and Neck (SCCHN)
Interventions: Metformin, Naproxen Sodium; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Minneapolis, Minnesota • New York, New York

Conditions: Healthy, Long QT Syndrome
Interventions: ERB-041; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Sickle Cell Anemia
Interventions: Prasugrel, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 11 more

Conditions: Atopic Dermatitis
Interventions: FB-401, Placebo; Biological
Lead sponsor: Forte Biosciences, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 15
States / cities: Fountain Valley, California • Fremont, California • Lake City, Florida + 12 more

Conditions: Friedreich Ataxia
Interventions: Buccal Swabs and Blood Draws; Diagnostic Test
Lead sponsor: Larimar Therapeutics, Inc.; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 20 participants
Timeline: 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hereditary Angioedema Types I and II
Interventions: Ecallantide subcutaneous dosing; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 2 Years to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Hemophilia B
Interventions: Non-Interventional; Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 16 Years and older · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 9
States / cities: Aurora, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 6 more

Conditions: Cerebral Adrenoleukodystrophy (CALD), Adrenoleukodystrophy (ALD), X-Linked Adrenoleukodystrophy (X-ALD)
Interventions: No interventional drug product utilized in this follow-up study; Genetic
Lead sponsor: Genetix Biotherapeutics Inc.; Industry
Eligibility: Up to 19 Years · Male only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2038
U.S. locations: 4
States / cities: Los Angeles, California • Palo Alto, California • Boston, Massachusetts + 1 more

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Parkinson's Disease, Parkinsonism, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, Shy-Drager Syndrome, Corticobasal Degeneration, Dementia With Lewy Bodies, Pick Disease, Olivopontocerebellar Atrophies
Interventions: Not listed
Lead sponsor: Bastyr University; Other
Eligibility: 19 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2030
U.S. locations: 1
States / cities: Kenmore, Washington

Conditions: Epidermolysis Bullosa
Interventions: ABH001, Control wound treatment; Biological · Other
Lead sponsor: Shire Regenerative Medicine, Inc.; Industry
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Phoenix, Arizona • Redwood City, California • San Diego, California + 3 more

Conditions: Huntington's Disease
Interventions: No Study Drug was Administered in this Study; Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 6
States / cities: Englewood, Colorado • Washington D.C., District of Columbia • Wichita, Kansas + 3 more

Conditions: Mucopolysaccharidosis IV A, Mucopolysaccharidosis VI
Interventions: Enzyme testing; Other
Lead sponsor: Children's Hospitals and Clinics of Minnesota; Other
Eligibility: Up to 21 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Saint Paul, Minnesota

Conditions: Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II
Interventions: In-home body weight support harness system; Other
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: Not listed
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cancer
Interventions: methotrexate, methylprednisolone, prednisone; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Methamphetamine Use Disorder, Drug Interaction, Cardiovascular Abnormalities
Interventions: Mirtazapine, Methamphetamine; Drug
Lead sponsor: San Francisco Department of Public Health; Government
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Los Angeles, California • San Francisco, California

Conditions: CLN6, Batten Disease, Batten's Disease, Neuronal Ceroid Lipofuscinosis CLN6, Neuronal Ceroid Lipofuscinosis
Interventions: scAAV9.CB.CLN6 (dose: 1.5E14 vector genomes); Drug
Lead sponsor: The Charlotte and Gwenyth Gray Foundation; Other
Eligibility: 4 Months and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Neurofibromatosis Type 1
Interventions: HLX-1502; Drug
Lead sponsor: Healx Limited; Industry
Eligibility: 12 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 10 more

Search by objective public record fields.

Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis

Patient-Empowered Mobile Technology in Hospitalized Patients (TRU-PAIN)

INdividualized ITI Based on Fviii(ATE) Protection by VWF

Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome

Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)

Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2

Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia

Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects

Prasugrel Versus Placebo in Adult Sickle Cell Disease

Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis

A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia

Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema

A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy

Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product

MENstrual Symptom Tracking to Understand and Assess (Women) Living With Cystic Fibrosis

Modifiable Variables in Parkinsonism (MVP)

A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing

Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease

Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip Disease

Body Weight Support Harness System in Spinal Muscular Atrophy

Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant

Mirtazapine and Methamphetamine Drug-drug Interaction Study

Gene Therapy Trial for CLN6 Batten Disease

A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1